Introduction {#s1}
============

Cognitive dysfunction is one of the core features of schizophrenia. Studies have shown that the average impairment in multiple domains of cognition in schizophrenia could reach 2 SD below healthy controls (HC).[@R1] Cognitive impairmentis evident in the prodromal stage, in patients with first-episode schizophrenia (FES) and even in patients with clinical high-risk psychosis (CHR-P) or high familial risk, and persist at a relatively stable level over time.[@R2] Previous studies suggested that patients with FES and CHR-P show worse performance in the speed of processing,[@R4] which may be the reason for deficits in other domains of cognition.[@R8] A meta-analysis of longitudinal studies in patients with FES and CHR-P suggested that cognitive impairment in schizophrenia could originate from abnormal neurodevelopment.[@R11] Imaging studies also supported these conclusions from the structural level.[@R12] Cognitive impairment is also an important cause of functional disability and an important factor predicting other outcomes that has a significant impact on patients' quality of life.[@R14]

The MATRICS Consensus Cognitive Battery (MCCB) was developed in 2004 to establish a standardised method to measure cognitive function to investigate cognitive-enhancing medications for schizophrenia.[@R15] It comprised 10 tests that assess seven cognitive domains including speed of processing, attention and vigilance, verbal learning, working memory, problem solving, visual learning and social cognition.[@R16]

MCCB has been translated into Chinese, and co-norming and standardisation has been done in China, showing sufficient clinical validity and reliability in controls and patients with schizophrenia.[@R17] Our literature search in various English and Chinese databases showed a growing number of studies on cognitive function in FES but a lack of systematic reviews summarising their data, especially for the reports published in Chinese. The systematic reviews done by Dickinson *et al*[@R8] focused on the domains of memory and the digital coding test, respectively. There have been a few meta-analysis including one by Mesholam-Gately *et al*[@R18] and a meta-analysis on drug-naive FES[@R19] but they were unable to include sufficient data from the Chinese population due to language limitations.[@R18] The Letter-Number Span (LNS) test was excluded from the original MCCB in China because there are no corresponding alphabets in Chinese. Cognitive measurements are often culturally affected in test batteries, especially in the domain of social cognition, so there may be differences in the profile of neurocognitive impairment in Chinese patients.[@R20] Another meta-analysis done by Zheng *et al* systematically reviewed cognitive impairment in patients with CHR-P but not with FES in the Chinese population.[@R21] It would be useful to compare our results to see changes in cognition between patients at different points in the course of their psychotic disease, and to further understand the development and course of cognitive impairment in schizophrenia.

In summary, it is necessary to systematically summarise the growing literature on cognitive impairment in Chinese patients with schizophrenia. This meta-analysis aims to review the baseline performance and impairment profile of MCCB of Chinese patients with FES, as well as its correlation with age and years of education. Given the impacts of cultural and social differences on neurocognitive testing, we also hope this meta-analysis could guide us in developing a neurocognitive test battery that is more appropriate for Chinese patients with schizophrenia.

Materials and methods {#s2}
=====================

Search strategy {#s2-1}
---------------

[Figure 1](#F1){ref-type="fig"} shows the process of the literature search. We conducted an electronic literature search in both Chinese and English databases up to 13 March 2019. Chinese and English keywords of 'Schizophrenia' AND 'cognition', AND 'Neuropsychological Tests' were used to search Pubmed, Embase, PsycINFO, Cochrane Library, China National Knowledge Infrastructure (CNKI), WANFANG DATA, WEIPU Journal Net(VIP) and Sino Biomedicine Service System (SinoMed). All literatures retrieved were loaded into Endnote X7 and duplicates were deleted. Two authors independently screened the titles and abstracts to identify possible articles for inclusion; reference lists from relevant review articles for additional studies were hand-searched. The two reviewers independently read the full texts and decided which studies to include according to the inclusion and exclusion criteria below. Disagreements between the two authors were resolved by discussions.

![Flowchart of identification of studies. HC, healthy controls; MCCB, MATRICS Consensus Cognitive Battery.](gpsych-2018-100043f01){#F1}

Inclusion and exclusion criteria {#s2-2}
--------------------------------

The following inclusion criteria were used based on PICOS: Participants (P): Chinese subjects with FES. Intervention (I): not applicable. Comparison (C): HCs. Outcomes (O): primary outcome was the overall cognitive function (composite score of MCCB); secondary outcomes included the seven MCCB cognitive domains: speed of processing, attention, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. Secondary outcomes also included nine subtests: Trail Making Test (TMT), Brief Assessment of Cognition in Schizophrenia-Symbol Coding, Hopkins Verbal Learning Test-Revised (HVLT-R), Wechsler Memory Scale III (WMS-III): Spatial Span, Neuropsychological Assessment Battery (NAB): Mazes, Brief Visuospatial Memory Test-Revised (BVMT-R), Category Fluency: Animal Naming, Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT): Managing Emotions, and Continuous Performance Test-Identical Pairs (CPT-IP). Study design (S): case--control studies. Studies were excluded if (1) the diagnosis was not clear or patients were not in first episode, and (2) they did not compare patients with HCs.

Data extraction {#s2-3}
---------------

Two authors (YZ and KM) independently checked and extracted the information included in the studies. If a study lacked SD data or not sure if the data they presented were a T score or raw score, the first or the corresponding author was contacted by email for more information. Any inconsistencies were resolved by consensus or involvement of a third reviewer (HZ). We divided the studies included in our systematic review according to whether they used T scores to report their outcomes or the raw scores, since the two types of scores could not be analysed or compared together. We reported our findings in two sections: the neurocognitive performance of Chinese patients with FES in the seven domains covered by the MCCB and their performance in the subtests of MCCB.

Statistical analysis {#s2-4}
--------------------

Data analyses were performed using the R software V.3.5.1, following the recommendation of the Cochrane Handbook for Systematic Reviews. A random effects model was used in all meta-analytical outcomes because heterogeneity was unavoidable in terms of sample size and sampling method of the studies. Since the outcome was reported using different scales in different studies, we used standardised mean differences (SMD) to evaluate the effect size of the meta-analytical results for all the continuous outcomes. We conducted mega-regression to analyse the effect of age and years of education on effect size. We also did sensitivity analysis, if the heterogeneity of effect size was higher than 50%, to identify the study which could account for more than 10% of the heterogeneity. Funnel plot and Egger test were conducted to explore public bias if the study number of an outcome was more than 10.

Assessment of study quality {#s2-5}
---------------------------

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)[@R22] and Grading of Recommendations Assessment, Development and Evaluation (GRADE)[@R23] were used to assess the quality of each study by two authors (YW and HZ) independently.

Results {#s3}
=======

We retrieved 858 records through literature search, no additional records were added through hand search of relevant reviews. Two hundred and twenty-seven duplicates were removed. Six hundred and thirty-one articles were screened for titles and abstracts and 537 reports were excluded according to the inclusion and exclusion criteria. Ninety-four full texts were examined, we excluded 16 articles because of overlapping data. Twenty studies did not offer meta-analysable data. It was not sure if the MCCB scores were T scores or raw scores in one study and there was a lack of SD data in another study, so we tried to contact the corresponding authors to clarify but got no response. Finally, 56 studies were included in the meta-analysis ([figure 1](#F1){ref-type="fig"}).

Study characteristics {#s3-1}
---------------------

Study and patient characteristics are summarised in [table 1](#T1){ref-type="table"}. All studies were conducted in China (n=56). The mean age of patients ranged from 13.8 to 32.39 and the mean age of healthy controls ranged from 13.79 to 44.7. The criteria used for FES included the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (33, 58.92%), the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)(1,1.8%);the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) (17, 30.36%), and the Chinese Classification of Mental Disorders, Third Edition (5, 8.93%); one study used DSM-IV or ICD-10 and three studies asked for Positive and Negative Syndrome Scale scores ≥60 in addition.

###### 

Characteristics of studies included in the meta-analysis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                 N\                 Subjects with FES      Healthy controls                                                                         
                        (nFES/nHC)                                                                                                                         
  --------------------- ------------------ ---------------------- ------------------ -------------- -------------- --------------- ------- --------------- --------------
  Liang *et al*[@R75]   32 (12/20)         ICD-10                 33.3               22.00          13.4 (1.9)     7.0             35.00   23.50           12.5 (3.1)

  Jiang *et al*[@R45]   46 (24/22)         ICD-10                 45.8               15.3 (2.5)     7.2 (3.9)      6.0             54.55   14.8 (2.9)      8.3 (2.2)

  Li *et al*[@R84]      93 (48/45)         CCMD-3                 62.5               25.9 (9.3)     10.6 (2.6)     NR              57.78   27.2 (11.9)     11.3 (3.6)

  Ai and Chen[@R46]     122 (60/62)        CCMD-3                 65.0               20.8 (7.9)     NR             NR              61.29   NR              NR

  Chen *et al*[@R47]    151 (79/72)        DSM-IV                 NR                 13.8 (1.45)    NR             4.16 (1.86)     41.67   13.79 (1.71)    NR

  Liu *et al*[@R48]     240 (120/120)      CCMD-3                 50.0               23 (10.2)      12.3 (3.1)     8 (7.4)         51.67   22 (9.8)        14.7 (2.6)

  Yang[@R49]            204 (102/102)      DSM-IV                 62.7               23.8 (3.4)     NR             NR              56.86   23.5 (3.1)      NR

  Shi *et al*[@R27]     60 (37/23)         ICD-10                 48.6               15.35 (1.53)   NR             NR              39.13   15.22 (1.53)    NR

  Zhao *et al*[@R66]    57 (20/37)         ICD-10                 55.0               21.45 (6.6)    10.95 (2.50)   NR              59.46   20.41 (6.126)   12.57 (2.41)

  Xiao *et al*[@R85]    60 (30/30)         DSM-IV                 50.0               23.5 (2.9)     12.3 (3.1)     NR              50.00   23.25 (4.21)    12.6 (2.03)

  Chen *et al*[@R28]    99 (49/50)         DSM-IV                 49.0               26.7 (8.5)     12.3 (1.45)    31.3 (14.1)     48.00   32.6 (9.3)      12.1 (1.8)

  Yao and Hu[@R30]      158 (83/75)        ICD-10                 77.1               23.15 (3.87)   12.7 (1.95)    6.48 (1.32)     73.33   25.23 (7.55)    15.21 (2.62)

  Hu *et al*[@R50]      154 (92/62)        DSM-IV                 65.2               21.19 (3.39)   11(2)          NR              59.68   21.89 (2.86)    10.83 (1.49)

  Zhang *et al*[@R67]   60 (30/30)         DSM-IV                 50.0               22.8 (4.2)     12.4 (1.5)     NR              50.00   23.8 (4.0)      12.5 (1.8)

  Liu *et al*[@R52]     155 (75/80)        DSM-IV                 54.7               23(3)          12.6 (2.8)     9 (11)          60.00   23(3)           14(2)

  Zhang *et al*[@R67]   54 (25/29)         DSM-IV                 44.0               15.3 (1.7)     8.7 (1.7)      5.6 (4.5)       44.83   15.5 (1.5)      8.6 (1.5)

  He *et al*[@R53]      148 (73/75)        DSM-IV                 58.9               24.05 (3.52)   14.52 (3.16)   NR              53.33   24.12 (3.48)    14.38 (3.09)

  Han *et al*[@R43]     82 (42/40)         DSM-IV                 28.6               20.5 (3.4)     12.6 (2.6)     NR              37.50   20.2 (1.9)      13.0 (1.3)

  Yang *et al*[@R54]    133 (79/54)        CCMD-3                 39.2               32.39 (11.2)   12.68 (3.06)   NR              27.78   32.24 (2.16)    13.54 (2.16)

  Zhang *et al*[@R55]   68 (41/27)         DSM-IV                 46.3               25(7)          13.2 (2.6)     NR              55.56   26(5)           13.9 (3.3)

  Chen *et al*[@R56]    102 (52/50)        ICD-10                 55.8               27.23 (9.36)   13.13 (3.21)   NR              52.00   28.35 (8.52)    12.67 (2.94)

  Ma *et al*[@R57]      97 (52/45)         DSM-IV                 42.3               NR             NR             NR              53.33   NR              NR

  Qi[@R59]              80 (40/40)         DSM-IV                 NR                 NR             NR             NR              NR      NR              NR

  Chen *et al*[@R56]    60 (30/30)         ICD-10                 53.3               23.85 (4.13)   10.92 (1.98)   NR              50.00   29.94 (4.08)    11.63 (1.89)

  Wei[@R41]             120 (60/60)        DSM-IV                 63.3               22.82 (6.56)   11.67 (2.83)   NR              56.67   20.97 (5.33)    11.82 (2.45)

  Chen *et al*[@R47]    210 (145/65)       DSM-IV                 51.7               28.5 (9.3)     13 (3.4)       18.5 (17.5)     53.85   27.6 (7.4)      12.6 (2.9)

  Huang *et al*[@R31]   101 (58/43)        ICD-10                 50.0               22.66 (7.64)   11.41 (2.73)   15.14 (20.01)   37.21   23.07 (7.49)    12.65 (3.81)

  Wu *et al*[@R32]      203 (79/124)       DSM-IV                 54.4               25.7 (7.8)     12.7 (3.2)     NR              52.42   44.7 (8.8)      11.8 (3.4)

  Zeng *et al*[@R33]    116 (55/61)        DSM-IV                 40.0               25 (6.36)      12.65 (2.89)   NR              45.90   25.33 (6.27)    12.74 (2.77)

  An *et al*[@R34]      60 (30/30)         DSM-IV                 NR                 NR             NR             NR              NR      NR              NR

  Chan *et al*[@R61]    138 (78/60)        DSM-IV                 62.8               28.5 (9.8)     10.8 (2.5)     8.2 (14.5)      31.67   28.5 (9.8)      10.8±2.5

  Chen *et al*[@R35]    132 (102/30)       DSM-IV                 47.1               27.37 (8.85)   12.53 (3.85)   NR              46.67   26.9 (5.2)      12.8 (3.8)

  Guo *et al*[@R62]     92 (51/41)         DSM-IV                 64.7               22.5 (4.1)     11.4 (3.3)     8.4 (6.8)       80.49   22.8 (3.9)      11.9 (2.7)

  He *et al*[@R63]      152 (80/72)        DSM-IV                 66.3               NR             NR             NR              NR      NR              NR

  Hou *et al*[@R64]     80 (40/40)         ICD-10                 60.0               26.4 (6.5)     8.6 (2)        NR              47.50   24.4±5.1        10.9 (2.2)

  Hu *et al*[@R50]      112 (56/62)        CCMD-3                 66.1               21.19 (3.39)   10.89 (1.76)   10.18 (6.76)    67.74   22 (4)          11 (1)

  Wang *et al*[@R40]    80 (40/40)         DSM-IV                 43.9               23.15 (7.52)   11.82 (3.84)   NR              47.63   34.54 (3.21)    10.56 (3.80)

  Chen *et al*[@R36]    78 (42/36)         DSM-IV                 42.8               25.21 (6.20)   12.22 (2.76)   16.1 (5.4)      58.30   26.47 (4.40)    14.17 (2.10)

  Liu *et al*[@R37]     116 (44/72)        DSM-IV                 70.5               23.5 (4.4)     11.9 (3.2)     NR              59.70   24.0 (2.9)      16.0 (2.3)

  Dong[@R76]            72 (42/30)         ICD-10                 61.9               27.02 (8.35)   11.43 (2.68)   NR              53.30   29.23 (5.52)    12.23 (1.79)

  Fu[@R68] \[68         60 (30/30)         DSM-IV/ICD-10          43.3               23.03 (3.64)   11.83 (3.15)   11.23 (5.47)    40.00   24.90 (3.83)    12.17 (2.73)

  Ge *et al*[@R83]      60 (30/30)         ICD-10                 53.3               25.23 (4.17)   13.73 (2.18)   6.49 (2.54)     NR      NR              NR

  Hao *et al*[@R38]     60 (30/30)         ICD-10                 56.7               15.41 (1.96)   NR             NR              56.70   15.57 (1.25)    NR

  Hu *et al*[@R72]      80 (42/38)         DSM-IV-TR              64.3               24.9 (4.8)     10.5 (2.8)     8.4 (2.6)       65.80   24.8 (4.6)      11.1 (2.9)

  Liu[@R39]             192 (142/50)       DSM-5 and PANSS ≥60    49.3               23.94 (5.5)    12.24 (2.88)   6.27 (3.83)     52.00   23.7 (4.9)      12.7 (3.6)

  Yu[@R69] \[69         114 (55/59)        ICD-10                 52.7               20.91 (4.87)   12 (6)         2 (11)          37.30   22.34 (4.06)    12 (4)

  Zhang *et al*[@R42]   83 (38/45)         ICD-10                 NR                 25.2 (6.0)     10.1 (2.7)     NR              NR      25.2 (5.3)      10.1 (3.0)

  Zhang *et al*[@R42]   64 (28/38)         DSM-IV                 50.0               21.9 (4.0)     12.8 (2.6)     NR              42.10   24.1 (4.4)      13.9 (2.6)

  Zhang[@R44]           61 (32/29)         DSM-IV                 68.8               22.7 (4.0)     13.1 (2.4)     10.3 (8.9)      58.60   22.1 (3.6)      13.8 (2.8)

  Zhao[@R81]            109 (50/59)        ICD-10 and PANSS ≥60   NR                 NR             NR             NR              NR      NR              NR

  Zhou[@R77]            186 (93/93)        ICD-10                 33.3               25.5 (6.2)     12.0 (2.2)     10 (median）    23.70   27.6 (2.7)      12.6 (1.4)

  Liang *et al*[@R70]   293 (98/195)       DSM-IV                 43.9               23.29 (6.79)   11.80 (2.66)   19.83 (28.81)   51.30   23.10 (5.45)    12.18 (2.91)

  Zhou *et al*[@R79]    98 (47/51)         DSM-IV                 59.6               25.5 (6.5)     14.1 (1.8)     12.8 (11.7)     42.90   24.3 (4.7)      16.1 (2.6)

  Zhou *et al*[@R80]    49 (32/17)         DSM-IV                 59.4               26.2 (8.1)     13.5 (2.2)     NR              76.50   25.5 (5.6)      12.6 (2.3)

  Zhou *et al*[@R78]    93 (51/42)         DSM-IV                 64.7               25.4 (6.8)     13.7 (2.2)     13.2 (11.7)     42.90   24.3 (4.7)      16.1 (2.6)

  Wang.[@R40]           205 (125/80)       DSM-IV and PANSS ≥60   49.0               23 (7)         12 (3)         6 (3)           52.00   24 (4)          13 (3)

  Sum                   6184 (3220/2972)                                                                                                                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

CCMD-3, Chinese Classification of Mental Disorders, Third Edition; DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; FES, first-episode schizophrenia; HC, health control;ICD-10, International Statistical Classification of Diseases and Related Health Problems, 10th Revision; NR, not reported; PANSS, Positive and Negative Syndrome Scale.

The STROBE score ranges from 0 to 22. Among the included 56 articles ([online supplementary table A1](#SP1){ref-type="supplementary-material"}), the highest score is 18, and the lowest is 1, with a mean (SD) of 11.41 (4.21). No study was considered of high quality. The main problems of most included studies are: (1) did not describe the setting, location and relevant dates, including periods of recruitment, exposure and data collection; (2) did not describe the aptitude of evaluators and consistencies among evaluators; (3) did not describe any efforts to address potential sources of bias; and (4) did not explain how the sample sizes were arrived at. The overall quality levels of 17 meta-analytical outcomes are evaluated as 'low' (5.9%, 1/17), 'moderate' (29.4%, 5/17) and 'high' (64.7%, 11/17) using the GRADE approach ([table 2](#T2){ref-type="table"}).
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###### 

GRADE analyses: neurocognitive dysfunction assessed by MCCB in subjects at clinical high risk for psychosis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Meta-analytical outcomes   Studies (n)   Risk of bias   Inconsistency   Indirectness   Imprecision   Publication bias   Large effect   Overall quality of evidence\*
  -------------------------- ------------- -------------- --------------- -------------- ------------- ------------------ -------------- -------------------------------
  Composite score            11 (1427)     No             Serious†        No             No            Serious            Large‡         +/+/+/−/\
                                                                                                                                         Moderate

  Speed of processing        7 (966)       No             Serious†        No             No            Serious            Large‡         +/+/+/−/\
                                                                                                                                         Moderate

  Attention/vigilance        11 (1487)     No             Serious†        No             No            No                 Large‡         +/+/+/+/\
                                                                                                                                         High

  Working memory             11 (1487)     No             Serious†        No             No            No                 Large‡         +/+/+/+/\
                                                                                                                                         High

  Verbal learning            12 (1569)     No             Serious†        No             No            No                 Large‡         +/+/+/+/\
                                                                                                                                         High

  Visual learning            12 (1569)     No             Serious†        No             No            No                 Large‡         +/+/+/+/\
                                                                                                                                         High

  Problem solving            11 (1487)     No             Serious†        No             No            No                 Large‡         +/+/+/+/\
                                                                                                                                         High

  Social cognition           12 (1570)     No             Serious†        No             No            No                 Large‡         +/+/+/+/\
                                                                                                                                         High

  TMT                        30 (3391)     No             Serious†        No             No            Serious            Large‡         +/+/+/−/\
                                                                                                                                         Moderate

  Symbol Coding              26 (2855)     No             Serious†        No             No            No                 Large‡         +/+/+/+/\
                                                                                                                                         High

  HVLT-R                     27 (2747)     No             Serious†        No             No            Serious            Large‡         +/+/+/−/\
                                                                                                                                         Moderate

  WMS-III-SS                 17 (1957)     No             Serious†        No             No            No                 No             +/+/+/−/\
                                                                                                                                         Moderate

  Mazes                      10 (1078)     No             Serious†        No             No            No                 Large‡         +/+/+/+/\
                                                                                                                                         High

  BVMT-R                     22 (2462)     No             Serious†        No             No            No                 Large‡         +/+/+/+/\
                                                                                                                                         High

  Fluency                    19 (1933)     No             Serious†        No             No            No                 Large‡         +/+/+/+/\
                                                                                                                                         High

  MSCEIT                     6 (706)       No             Serious†        No             No            Serious            No             +/+/−/−/\
                                                                                                                                         Low

  CPT-IP                     11 (945)      No             Serious†        No             No            No                 Large‡         +/+/+/+/\
                                                                                                                                         High
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*GRADE Working Group grades of evidence: high quality=further research is very unlikely to change our confidence in the estimate of effect; moderate quality=further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low quality=further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low quality=we are very uncertain about the estimate.

†All studies reported having a serious inconsistency had I^2^ \>50%.

‡Studies with large effects provided increased quality of evidence. Large effects=standard mean differences less than −0.8.

BVMT-R, Brief Visuospatial Memory Test-Revised; CPT-IP, Continuous Performance Test-Identical Pair; GRADE, Grading of Recommendations Assessment, Development and Evaluation; HVLT-R, Hopkins Verbal Learning Test-Revised; MCCB, MATRICS Consensus Cognitive Battery; MSCEIT, Mayer-Salovey-Caruso Emotional Intelligence Test; TMT, Trail Making Test; WMS-III-SS, Wechsler Memory Scale III: Spatial Span.

MCCB cognitive domain score comparison between patients with FES and HCs {#s3-2}
------------------------------------------------------------------------

### MCCB composite score {#s3-2-1}

Pooling data from 12 studies that contained MCCB composite scores of patients with FES and HCs (FES=788, HC=639),[@R27] the MCCB composite score was significantly lower in patients with FES than controls (SMD=−1.60, 95% CI −1.82 to −1.38, *I*^2^=67%) ([figures 2 and 3](#F2 F3){ref-type="fig"}). Sensitivity analysis found that one study[@R33] contributed to the heterogeneity of effect size most, and *I*^2^ decreased to zero when omitting this study.

![MCCB cognitive domain score comparison between patients with first-episode schizophrenia (FES) and healthy controls. MCCB, MATRICS Consensus Cognitive Battery; SMD, standardised mean difference.](gpsych-2018-100043f02){#F2}

![MATRICS Consensus Cognitive Battery (MCCB) composite score comparison between patients with first-episode schizophrenia (FES) and HC. HC, healthy control; SCZ, schizophrenia; SMD, standardised mean difference.](gpsych-2018-100043f03){#F3}

### Speed of processing {#s3-2-2}

Pooling data from seven studies that contained speed of processing T scores of patients with FES and HCs (FES=549, HC=417),[@R30] the speed of processing domain score was significantly lower in the patients with FES than the controls (SMD=−1.41, 95% CI −1.75 to −1.06, *I*^2^=82%) ([online supplementary figure A1](#SP1){ref-type="supplementary-material"}; [figure 2](#F2){ref-type="fig"}). Sensitivity analysis found that *I*^2^ decreased to 67.5% when omitting the study[@R39] that contributed most to the heterogeneity of the effect size.

### Attention/vigilance {#s3-2-3}

Pooling data from 11 studies that contained attention and vigilance T scores of patients with FES and HCs (FES=818, HC=669),[@R30] the attention and vigilance domain score was significantly lower in the patients with FES than the controls (SMD=−1.40, 95% CI −1.78 to −1.01, *I*^2^=90%) ([online supplementary figure A2](#SP1){ref-type="supplementary-material"}; [figure 2](#F2){ref-type="fig"}). Sensitivity analysis found *I*^2^ decreased to 75.2% when omitting the study[@R39] that contributed most to the heterogeneity of the effect size.

### Working memory {#s3-2-4}

Pooling data from 11 studies that contained working memory T scores of patients with FES and HCs (FES=818, HC=669),[@R30] the working memory domain score was significantly lower in the patients with FES than the controls (SMD=−1.08, 95% CI −1.38 to −0.77, *I*^2^=86%) ([online supplementary figure A3](#SP1){ref-type="supplementary-material"}; [figure 2](#F2){ref-type="fig"}). Sensitivity analysis found *I*^2^ decreased to 73.9% when omitting the study[@R39] that contributed most to the heterogeneity of the effect size.

### Verbal learning {#s3-2-5}

Pooling data from 12 studies that contained verbal learning scores of patients with FES and HCs (FES=860, HC=709),[@R30] the verbal learning domain score was significantly lower in the patients with FES than the controls (SMD=−1.04, 95% CI −1.23 to −0.85, *I*^2^=66%) ([online supplementary figure A4](#SP1){ref-type="supplementary-material"}; [figure 2](#F2){ref-type="fig"}). Sensitivity analysis found *I*^2^ decreased to 33.5% when omitting the study[@R39] that contributed most to the heterogeneity of the effect size.

### Visual learning {#s3-2-6}

Pooling data from 12 studies that contained visual learning scores of patients with FES and HCs (FES=860, HC=709),[@R30] the visual learning domain score was significantly lower in the patients with FES than the controls (SMD=−1.14, 95% CI −1.37 to −0.91, *I*^2^=77%) ([online supplementary figure A5](#SP1){ref-type="supplementary-material"}; [figure 2](#F2){ref-type="fig"}). Sensitivity analysis found *I*^2^ decreased to 63.3% when omitting the study[@R39] that contributed most to the heterogeneity of the effect size.

### Problem solving {#s3-2-7}

Pooling data from 11 studies that contained problem solving scores of patients with FES and HCs (FES=818, HC=669),[@R30] the problem solving domain score was significantly lower in the patients with FES than the controls (SMD=−1.04, 95% CI −1.28 to −0.80, *I*^2^=77%) ([online supplementary figure A6](#SP1){ref-type="supplementary-material"}; [figure 2](#F2){ref-type="fig"}). Sensitivity analysis found *I*^2^ did not decrease much when omitting any study.

### Social cognition {#s3-2-8}

Pooling data from 12 studies that contained social cognition scores of patients with FES and HCs (FES=856, HC=714),[@R30] the social cognition domain score was significantly lower in the patients with FES than the controls (SMD=−0.87, 95% CI −1.21 to −0.53, *I*^2^=90%) ([online supplementary figure A7](#SP1){ref-type="supplementary-material"}; [figure 2](#F2){ref-type="fig"}). Sensitivity analysis found *I*^2^ decreased to 77.0% when omitting the study[@R39] that contributed most to the heterogeneity of the effect size.

MCCB subtest score comparison between patients with FES and HCs {#s3-3}
---------------------------------------------------------------

### Trail Making Test {#s3-3-1}

Pooling data from 30 studies that contained TMT scores (completion time) of patients with FES and HCs (FES=1663, HC=1650), the TMT completion time was significantly longer in the patients with FES than the controls (SMD=1.36, 95% CI 1.15 to 1.58, *I*^2^=89%), which indicated that patients with FES had worse performance in TMT than controls(SMD=-1.36, 95% CI -1.58to -1.15) ([online supplementary figure A8](#SP1){ref-type="supplementary-material"}; [figure 4](#F4){ref-type="fig"}).[@R27] Sensitivity analysis found *I*^2^ did not decrease much when omitting any study.

![MCCB subtest score comparison between patients with first-episode schizophrenia (FES) and healthy controls. BVMT, Brief Visuospatial Memory Test; CPT, Continuous Performance Test; HVLT, Hopkins Verbal Learning Test; MCCB, MATRICS Consensus Cognitive Battery; MSCEIT, Mayer-Salovey-Caruso Emotional Intelligence Test; SMD, standardised mean difference; TMTA, Trail Making Test-A.](gpsych-2018-100043f04){#F4}

### Symbol Coding test {#s3-3-2}

Pooling data from 26 studies that contained Symbol Coding subtest raw scores of patients with FES and HCs (FES=1551, HC=1304),[@R27] the Symbol Coding score was significantly lower in the patients with FES than the controls (SMD=−1.90, 95% CI −2.13 to −1.67, *I*^2^=84%) ([online supplementary figure A9](#SP1){ref-type="supplementary-material"}; [figure 4](#F4){ref-type="fig"}). Sensitivity analysis found *I^2^* did not decrease much when omitting any study.

### Hopkins Verbal Learning Test-Revised {#s3-3-3}

Pooling data from 27 studies that contained HVLT-R subtest raw scores of patients with FES and HCs (FES=1448, HC=1299),[@R27] the HVLT-R score was significantly lower in the patients with FES than the controls (SMD=−1.24, 95% CI −1.48 to −1.00, *I*^2^=87%) ([online supplementary figure A10](#SP1){ref-type="supplementary-material"}; [figure 4](#F4){ref-type="fig"}). Sensitivity analysis found *I^2^* did not decrease much when omitting any study.

### WMS-III: Spatial Span {#s3-3-4}

Pooling data from 17 studies that contained Spatial Span subtest raw scores of patients with FES and HCs (FES=1044, HC=913),[@R27] the Spatial Span test score was moderately lower in the patients with FES than the controls (SMD=−0.69, 95% CI −0.84 to −0.55, *I*^2^=53%) ([online supplementary figure A11](#SP1){ref-type="supplementary-material"}; [figure 4](#F4){ref-type="fig"}). Sensitivity analysis found *I^2^* did not decrease much when omitting any study.

### NAB: Mazes {#s3-3-5}

Pooling data from 10 studies that contained Mazes subtest raw scores of patients with FES and HCs (FES=590, HC=488),[@R27] the Mazes test score was significantly lower in the patients with FES than the controls (SMD=−1.16, 95% CI −1.49 to −0.84, *I*^2^=82%) ([online supplementary figure A12](#SP1){ref-type="supplementary-material"}; [figure 4](#F4){ref-type="fig"}). Sensitivity analysis found *I^2^* decreased to 51.1% when omitting the study[@R77] which contributed most to heterogeneity.

### Brief Visuospatial Memory Test-Revised {#s3-3-6}

Pooling data from 22 studies that contained BVMT-R subtest raw scores of patients with FES and HCs (FES=1290, HC=1172),[@R27] the BVMT-R score was significantly lower in the patients with FES than the controls (SMD=−1.18, 95% CI −1.33 to −1.03, *I*^2^=65%) ([online supplementary figure A13](#SP1){ref-type="supplementary-material"}; [figure 4](#F4){ref-type="fig"}). Sensitivity analysis found *I^2^* did not decrease much when omitting any study.

### Category Fluency: Animal Naming (Fluency) {#s3-3-7}

Pooling data from 19 studies that contained Animal Naming Fluency subtest raw scores of patients with FES and HCs (FES=1047, HC=886),[@R27] the Category Fluency test score was significantly lower in the patients with FES than the controls (SMD=−1.01, 95% CI −1.21 to −0.82, *I*^2^=74%) ([online supplementary figure A14](#SP1){ref-type="supplementary-material"}; [figure 4](#F4){ref-type="fig"}). Sensitivity analysis found *I*^2^ decreased to 62.8% when omitting the study[@R28] that contributed most to the heterogeneity.

### MSCEIT: Managing Emotions {#s3-3-8}

Pooling data from six studies that contained MSCEIT subtest raw scores of patients with FES and HCs (FES=401, HC=305),[@R28] the MSCEIT test raw score was slightly lower in the patients with FES than the controls (SMD=−0.38, 95% CI −0.64 to −0.13, *I*=60%) ([online supplementary figure A15](#SP1){ref-type="supplementary-material"}; [figure 4](#F4){ref-type="fig"}). Sensitivity analysis found *I^2^* did not decrease much when omitting any study.

### Continuous Performance Test-Identical Pairs {#s3-3-9}

Pooling data from 11 studies that contained CPT-IP subtest raw score of patients with FES and HCs (FES=535, HC=410),[@R27] the CPT-IP score was significantly lower in the patients with FES than the controls (SMD=−1.33, 95% CI −1.66 to −1.00, *I*^2^=80%) ([online supplementary figure A16](#SP1){ref-type="supplementary-material"}; [figure 4](#F4){ref-type="fig"}). Sensitivity analysis found *I^2^* did not decrease much when omitting any study.

Meta-regression {#s3-4}
---------------

Most studies provided data on age and education years. Meta-regression was conducted to explore the influence of these moderators. It was found that there was a positive correlation between age and SMD of BVMT (coefficient=0.05, z-value=3.18, R^2^=55.84%), and a small BVMT score difference was found in the younger population group; there was no significant correlation between age and other outcomes. Education years had no significant influence on the study effect size.

Publication bias {#s3-5}
----------------

Except for the result of speed of processing and MSCEIT, Egger test was conducted to identify publication bias of all other outcomes. Egger test showed there may be potential publication bias in MCCB composite score (t=−2.99, df=10, p=0.013), TMT (t=3.40, df=28, p\<0.01) and HVLT-R (t=−3.76, df=25, p\<0.01). Funnel plot of MCCB composite score also showed there was asymmetry in the figure ([figure 5](#F5){ref-type="fig"}).

![Funnel plot of MATRICS Consensus Cognitive Battery (MCCB) composite score.](gpsych-2018-100043f05){#F5}

Discussion {#s4}
==========

Main findings {#s4-1}
-------------

To the best of our knowledge, this was the first meta-analysis that systematically explores neurocognitive function in Chinese patients with FES from the point of view of MCCB results. Compared with HCs, in Chinese patients with FES, significant deficit was found in MCCB composite score (SMD=−1.60, 95% CI −1.82 to −1.38) and all seven cognitive domains. The pooled effect sizes were the greatest in speed of processing and attention, followed by visual learning, working memory, verbal learning, problem solving, social cognition, with SMD between −0.87 and −1.41 in seven cognitive domains. The ranks of SMD of nine MCCB subtest raw scores were as follows: Symbol Coding, TMT, CPT-IP, HVLT, BVMT, Mazes, Category Fluency, Spatial Span, MSCEIT, with pooled effect sizes from −0.38 to −1.90. Age and years of education may have no significant influence on the effect size of studies except for SMD of BVMT, which had a positive correlation with age.

Implications {#s4-2}
------------

Our results on the seven cognitive domains and on each MCCB subset both showed the worst impairment in speed of processing and attention/vigilance and the least impairment in social cognition. Although the rank between decline in verbal memory, visual memory, problem solving and working memory is not consistent in the two results, the effect sizes are large and comparable in verbal memory, visual memory and problem solving. A meta-analysis of Xiang *et al* that focused on patients with CHR-P in China also showed the greatest deficits in the speed of processing and attention/vigilance, while suggesting no statistically significant impairment in social cognition. Our study showed a slightly greater deficit in all of the seven cognitive domains of patients with FES compared with patients with CHR-P. There is also a difference in the order of which working memory, problem solving, visual learning and verbal learning are ranked according to their level of impairment.[@R21] These results could suggest that cognitive impairment continues to progress from the time patients are defined as CHR-P to the start of the first episode, and that different domains of cognition may deteriorate at different rates throughout the course of the disease. This correlates with a meta-analysis on neurocognition in CHR-P young adults who did or did not convert to FES, which concluded that the main difference in the cognitive profile of the two populations is in the domains of working memory and visual learning.[@R86]

The findings of our study showed a higher level of impairment in all seven domains of neurocognition among patients with FES compared with the results from the meta-analysis done by Mesholam-Gately *et al*.[@R18] The effect size for HVLT and WMS-III: Spatial Span falls into the range reported by Mesholam-Gately *et al*[@R18] while SMDs of Symbol Coding and TMT-A were lower in our study. Interestingly, Chinese patients with FES seem to have less impairment in social cognition. These differences could result from the fact that the other study included research that used cognitive tests not included in the MCCB, and that the tests were grouped differently into various cognitive domains than the MCCB. Furthermore, the Chinese version of MCCB does not have a LNS test that accounts for working memory, which, along with other differences in cultural and language differences, could also lead to discrepancies in the test results across different countries.

Given the potential difference caused by the usage of MCCB in China, it would be interesting to compare the normative data of MCCB with other countries, and to create a neurocognitive test battery that better adapts to the characteristics of Chinese patients with schizophrenia. More research on social cognition in Chinese patients as well as high-quality studies investigating the role of medications and other treatments such as electroconvulsive therapy and transcranial magnetic stimulation in improving cognitive function in patients with schizophrenia are needed. Further studies on longitudinal change in neurocognitive decline in patients with schizophrenia would be helpful in understanding the mechanisms and finding new therapeutic targets. Being the first systematic review on previous literature regarding Chinese patients with FES, this study provides a summary and serves as a basis for future research on this topic.

Strengths and limitations of this study {#s4-3}
---------------------------------------

The main strength of this meta-analysis was that it included studies with MCCB domain score and studies providing MCCB subset raw score, which would enlarge the sample size and enhance certainty of the results. However, the limitations of this study should also be acknowledged. First, among all studies included, no literature was rated as high quality according to STROBE, but most outcomes were rated as high quality using GRADE; the potential reason may be that STROBE and GRADE assess different aspects. The studies we included were cross-sectional studies, we think STROBE shows more precise information. Second, considerable heterogeneity of SMD existed in some results, so we conducted meta-regression to analyse the impact of some possible moderators and sensitivity analysis to find out extreme or abnormal values; by these methods heterogeneity could partially be explained. However, the effects of some potential moderators such as clinical symptoms severity, medication and premorbid IQ were not explored because they were not frequently provided in studies. It is shown in several studies that antipsychotics have a limited effect on cognitive function early in FES.[@R87] We originally planned to conduct a subgroup analysis for treated patients and treatment-naive patients. However, we found that very few of the studies included in this review mentioned if the patients had already taken antipsychotics at the time of neurocognitive evaluation. Therefore, the amount of data was not sufficient to perform a subgroup analysis. Third, there was a potential publication bias for the primary outcome MCCB composite score. Considering the limited number of studies, more studies are warranted to confirm our results in the future.

Conclusion {#s5}
==========

In summary, the Chinese patients with FES performed worse than the HCs in the overall neurocognitive function and all individual cognitive domains. Prominent impairment was particularly seen in Symbol Coding, TMT and CPT-IP, namely in the neurocognitive domains of speed of processing and attention. On the one hand, the result indicates that some neuropsychological tasks are more sensitive and reflect relatively more severe cognitive deficits, which may shed light on the development of new neurocognitive assessment batteries. On the other hand, it reminds us that early effective interventions should be developed and implemented to relieve cognitive damage in Chinese patients with FES.
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